SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001479290-24-000009
Filing Date
2024-01-08
Accepted
2024-01-08 08:01:42
Documents
14
Period of Report
2024-01-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rvnc-20240108.htm   iXBRL 8-K 30250
2 EX-99.1 rvncjan24jpm8-k_exhibit991.htm EX-99.1 54072
6 logohighresa.gif GRAPHIC 38132
  Complete submission text file 0001479290-24-000009.txt   278114

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20240108.xsd EX-101.SCH 1939
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20240108_lab.xml EX-101.LAB 24139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20240108_pre.xml EX-101.PRE 12544
8 EXTRACTED XBRL INSTANCE DOCUMENT rvnc-20240108_htm.xml XML 2741
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 24518408
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)